Mind Medicine (MindMed) (MNMD) Stock Forecast, Price Target & Predictions
MNMD Stock Forecast
Mind Medicine (MindMed) stock forecast is as follows: an average price target of $14.00 (represents a 95.53% upside from MNMD’s last price of $7.16) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
MNMD Price Target
The average price target for Mind Medicine (MindMed) (MNMD) is $14.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 95.53% upside from MNMD's last price of $7.16.
MNMD Analyst Ratings
According to 3 Wall Street analysts, Mind Medicine (MindMed)'s rating consensus is 'Buy'. The analyst rating breakdown for MNMD stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Mind Medicine (MindMed) Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Sumart Kulkami | Canaccord Genuity | $14.00 | $6.45 | 117.05% | 95.53% |
| Jun 05, 2024 | Brian Abrahams | RBC Capital | $22.00 | $8.25 | 166.67% | 207.26% |
| May 13, 2024 | Francois Brisebois | Oppenheimer | $20.00 | $8.61 | 132.42% | 179.33% |
| Nov 16, 2022 | RBC Capital | $5.00 | $2.86 | 74.83% | -30.17% |
The latest Mind Medicine (MindMed) stock forecast, released on Sep 16, 2024 by Sumart Kulkami from Canaccord Genuity, set a price target of $14.00, which represents a 117.05% increase from the stock price at the time of the forecast ($6.45), and a 95.53% increase from MNMD last price ($7.16).
Mind Medicine (MindMed) Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $18.67 |
| Last Closing Price | $7.16 | $7.16 | $7.16 |
| Upside/Downside | -100.00% | -100.00% | 160.75% |
In the current month, the average price target of Mind Medicine (MindMed) stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mind Medicine (MindMed)'s last price of $7.16. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jun 05, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 13, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Nov 16, 2022 | RBC Capital | Outperform | Initialise | |
| Aug 26, 2022 | Oppenheimer | Outperform | Initialise |
Mind Medicine (MindMed)'s last stock rating was published by Canaccord Genuity on Sep 16, 2024. The company gave MNMD a "Buy" rating, the same as its previous rate.
Mind Medicine (MindMed) Financial Forecast
Mind Medicine (MindMed) Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Mind Medicine (MindMed)'s average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MNMD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Mind Medicine (MindMed) EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict MNMD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mind Medicine (MindMed)'s previous annual EBITDA (undefined) of $NaN.
Mind Medicine (MindMed) Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-26.48M | $-29.05M | $-27.76M | $-27.28M | $-24.78M | $-22.23M | $-23.52M |
| High Forecast | $-26.48M | $-29.05M | $-27.76M | $-27.28M | $-23.28M | $-22.23M | $-23.52M |
| Low Forecast | $-26.48M | $-29.05M | $-27.76M | $-28.08M | $-25.54M | $-22.23M | $-23.52M |
| Surprise % | - | - | - | - | - | - | - |
Mind Medicine (MindMed)'s average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MNMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Mind Medicine (MindMed) SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Mind Medicine (MindMed)'s average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MNMD last annual SG&A of $NaN (undefined).
Mind Medicine (MindMed) EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.33 | $-0.36 | $-0.35 | $-0.34 | $-0.31 | $-0.28 | $-0.33 |
| High Forecast | $-0.33 | $-0.36 | $-0.35 | $-0.34 | $-0.29 | $-0.28 | $-0.33 |
| Low Forecast | $-0.33 | $-0.36 | $-0.35 | $-0.35 | $-0.32 | $-0.28 | $-0.33 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Mind Medicine (MindMed)'s projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MNMD previous annual EPS of $NaN (undefined).
Mind Medicine (MindMed) Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RVPH | Reviva Pharmaceuticals | $1.40 | $10.00 | 614.29% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| CKPT | Checkpoint Therapeutics | $3.72 | $20.00 | 437.63% | Buy |
| ATAI | Atai Life Sciences | $1.32 | $6.00 | 354.55% | Buy |
| ITOS | iTeos Therapeutics | $7.69 | $33.50 | 335.63% | Buy |
| OPT | Opthea | $3.27 | $14.00 | 328.13% | Buy |
| GHRS | GH Research | $8.46 | $28.00 | 230.97% | Buy |
| MNMD | Mind Medicine (MindMed) | $7.48 | $14.00 | 87.17% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| KOD | Kodiak Sciences | $8.87 | $11.00 | 24.01% | Buy |